Navigation Links
Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis

es in RRMS. The most common side effects of COPAXONE(R) are redness, pain, swelling, itching, a lump or an indentation at the site of injection, weakness, infection, pain, nausea, joint pain, anxiety, and muscle stiffness.

COPAXONE(R) is now approved in 47 countries worldwide, including the United States, Canada, Mexico, Australia, Israel, and all European countries. In Europe, COPAXONE(R) is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. In North America, COPAXONE(R) is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA). COPAXONE(R) is a registered trademark of Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

See additional important information at http://www.copaxone.com/pi/index.html or call 1-800-887-8100 for electronic releases. For hardcopy releases, please see enclosed full prescribing information.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:7/24/2008)...- Ortho-McNeil Neurologics, a,division of Ortho-Mc...y,that the U.S. Food and Drug Administration (FDA)...(topiramate), based on studies submitted in,respon...the use of TOPAMAX,in pediatric patients aged 1 to...ion to granting pediatric exclusivity, the FDA is ...
(Date:7/24/2008)...ncology Patient Accrual, DENVER, July 24 /PRNewsw...ganization (RMO), has contracted with five leading...site management services for their,clinical trials... The new,trials include the following disease indi...atic Breast Cancer, Metastatic Sarcoma, Chronic My...
(Date:7/23/2008)...y print edition of Clinical C... /- A Roche Diagnostics-sponsored,pil...pe natriuretic peptide,(NT-proBNP) confirms the po... in predicting the risk of cardiovascular adverse ...dal anti-inflammatory drugs of,the COX inhibitor c...
(Date:7/23/2008)...nCode BioPharmaceutics, Inc.,an emerging biopharm...t,results demonstrating the utility of their lead ... chronic blood disorder paroxysmal nocturnal,hemog...ented at the XXII,International Complement Worksho... only treatment currently available for PNH patien...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Cancer researchers seek safe reduction of radiotherapy 2663 1Cancer researchers seek safe reduction of radiotherapy 2663 2New clinical guideline for low back pain 2661 1New clinical guideline for low back pain 2661 2New clinical guideline for low back pain 2661 3Vaginal progesterone gel may improve infant outcomes and 2659 1Vaginal progesterone gel may improve infant outcomes and 2659 2Vaginal progesterone gel may improve infant outcomes and 2659 3Vaginal progesterone gel may improve infant outcomes and 2659 4Drug Combo Helps Fight Marfan Syndrome 2658 1Drug Combo Helps Fight Marfan Syndrome 2658 2
...ERYVILLE, Calif., April 16, 2007 /PRNewswire-First...e mechanism of action of,its anti-cancer agent BZL...ing for late stage breast cancer at the American,A... the Los Angeles,Convention Center in Los Angeles,...ntation will describe the pathway for,cancer cell ...
...USAND OAKS, Calif.--(BUSINESS WIRE)--Apr 16, 2007 ...from a randomized,double-blind, placebo-controlle... of Aranesp(R) (darbepoetin alfa) for the,treatmen...eiving,chemotherapy or radiotherapy ("the 103 stud... EMEA in these patients. These,results were presen...
Other Medicine Technology:Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 2Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Retina Group of New York will...ted macular degeneration especially designed for s...e Public Library at 116 Merritts Road, Farmingdale.... Attendance is free and refreshments will be prov...6) 939-6100. , Hicksville...
(Date:7/25/2008)... This donation will be used to fac...ve services for children , ... ( www.ivci.com ), a leading integrator of enterp...tion video conferencing, telepresence, audio visua...announced today that it has donated video conferen...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2
...ncer, such as radiotherapy, surgery and drugs as w...edical training// vary throughout the EU, accordin... Medical Oncology (ESMO) on 3 October 2006. Access...om country to country. The survey published in Me...
...ur of daily physical exercise for their future goo...agues at Glasgow University studied 545 children a...red the children who had the recommended adult lev...s, three times a week, reported the online edition...
...al health wards have been graded as unpleasant or ...atients//. The charity called Mind revealed that ...te of repair of their ward while 28% were not sati...Mind is for patients to be treated in a therapeuti...
...erts, some cancer patients are experiencing unjust...te of the new legislation to protect their rights/...fect from the end of last year has provided effect...h severe illnesses like cancer, multiple sclerosis...
Other Medicine News:Health News:Mental Health Wards rated unpleasant 2Health News:Injustice to cancer patients at work 2
Acetate Plate Sealers 100/Box
...croseal 'B' seals provide an adhesive-based sealin...tes. The aggressive adhesive layer ensures secure ...g, and tight sealing during thermal cycling when s...he perforated end-tabs can be removed when using t...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape.
Inquire
Medicine Products: